Wolf H Fridman

List of Publications by Year in Descending Order

46 papers	5,980 citations	30 h-index	48 g-index
48 ext. papers	8,198 ext. citations	9.4 avg, IF	5.66 L-index

#	Paper	IF	Citations
46	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.. *Nature Reviews Clinical Oncology*, **2022**,	19.4	7
45	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. *Frontiers in Oncology*, **2021**, 11, 643065	5.3	6
44	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. *Cancer Immunology Research*, **2021**, 9, 891-908	12.5	7
43	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.. *Nature Cancer*, **2021**, 2, 794-802	15.4	19
42	Complement System: Promoter or Suppressor of Cancer Progression?. *Antibodies*, **2020**, 9,	7	13
41	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. *Frontiers in Immunology*, **2020**, 11, 784	8.4	98
40	B cells are associated with survival and immunotherapy response in sarcoma. *Nature*, **2020**, 577, 556-560	50.4	538
39	Therapeutic Targeting of the Colorectal Tumor Stroma. *Gastroenterology*, **2020**, 158, 303-321	13.3	23
38	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. *Genome Medicine*, **2020**, 12, 86	14.4	17
37	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. *Cancer Immunology Research*, **2019**, 7, 1091-1105	12.5	68
36	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 474, 463-474	5.1	12
35	Immune-based identification of cancer patients at high risk of progression. *Current Opinion in Immunology*, **2018**, 51, 97-102	7.8	12
34	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. *Cancer Immunology, Immunotherapy*, **2018**, 67, 981-988	7.4	58
33	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. *Frontiers in Oncology*, **2018**, 8, 390	5.3	31
32	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. *Clinical Cancer Research*, **2017**, 23, 4416-4428	12.9	174
31	The immune contexture in cancer prognosis and treatment. *Nature Reviews Clinical Oncology*, **2017**, 14, 717-734	19.4	935
30	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. *Advances in Immunology*, **2016**, 130, 95-190	5.6	120

29	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biology*, **2016**, 17, 218	18.3	791
28	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. *Clinical Cancer Research*, **2015**, 21, 3031-40	12.9	249
27	PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. *Cancer Research*, **2013**, 73, 128-38	10.1	456
26	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. *OncoImmunology*, **2012**, 1, 326-333	7.2	85
25	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. *Frontiers in Immunology*, **2011**, 2, 66	8.4	7
24	Immune infiltration in human cancer: prognostic significance and disease control. *Current Topics in Microbiology and Immunology*, **2011**, 344, 1-24	3.3	126
23	A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. *Journal of Immunotherapy*, **2010**, 33, 991-8	5	161
22	Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. *Head and Neck*, **2010**, 32, 946-58	4.2	42
21	Revisiting the prognostic value of regulatory T cells in patients with cancer. *Journal of Clinical Oncology*, **2009**, 27, e5-6; author reply e7	2.2	33
20	The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. *Cancer Research*, **2008**, 68, 3907-14	10.1	57
19	B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. *Journal of Immunology*, **2007**, 179, 3371-9	5.3	44
18	Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. *Clinical Cancer Research*, **2006**, 12, 465-72	12.9	441
17	The SH2 domain-containing inositol 5-phosphatase SHIP1 is recruited to the intracytoplasmic domain of human FcgammaRIIB and is mandatory for negative regulation of B cell activation. *Immunology Letters*, **2006**, 104, 156-65	4.1	25
16	Two distinct tyrosine-based motifs enable the inhibitory receptor FcgammaRIIB to cooperatively recruit the inositol phosphatases SHIP1/2 and the adapters Grb2/Grap. *Journal of Biological Chemistry*, **2004**, 279, 51931-8	5.4	38
15	Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. *Blood*, **2002**, 99, 2114-21	2.2	266
14	Negative regulation of mast cell proliferation by FcgammaRIIB. *Molecular Immunology*, **2002**, 38, 1295-9	4.3	38
13	Src homology 2 domain-containing inositol 5-phosphatase 1 mediates cell cycle arrest by FcgammaRIIB. *Journal of Biological Chemistry*, **2001**, 276, 30381-91	5.4	21
12	Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. *Journal of Immunology*, **2001**, 166, 531-7	5.3	200

11	Insufficient phosphorylation prevents fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1. *Journal of Biological Chemistry*, **2001**, 276, 6327-36	5.4	35
10	SHIP1-mediated negative regulation of cell activation and proliferation by FcRIIB **2001**, 141-152		
9	Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB. *Journal of Biological Chemistry*, **2000**, 275, 37357-64	5.4	73
8	Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. *Journal of Biological Chemistry*, **1999**, 274, 32493-9	5.4	55
7	Cytokines and cell regulation. *Molecular Aspects of Medicine*, **1997**, 18, 3-90	16.7	9
6	Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gammaRIIB during negative regulation of IgE-dependent mouse mast cell activation. *Immunology Letters*, **1996**, 54, 83-91	4.1	111
5	The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. *Immunity*, **1995**, 3, 635-46	32.3	403
4	Distinct intracytoplasmic sequences are required for endocytosis and phagocytosis via murine Fc gamma RII in mast cells. *International Immunology*, **1993**, 5, 1393-401	4.9	44
3	Receptors for immunoglobulin isotypes (FcR) on murine T cells. I. Multiple FcR expression on T lymphocytes and hybridoma T cell clones. *European Journal of Immunology*, **1985**, 15, 662-7	6.1	30
2	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression		1
1	webMCP-counter: a web interface for transcriptomics-based quantification of immune and stromal cells in heterogeneous human or murine samples		1